目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T41256 | Aurora Kinase | ||
SP-96 是一种高效的特异性 Aurora B 抑制剂,IC50 为 0.316 nM。 SP-96 在 NCI60 筛选中显示特异性生长抑制,如 MDA-MD-468 (GI50=107 nM)。 SP-96 可用于三阴性乳腺癌研究。 | |||
T6126 | Apoptosis CDK Aurora Kinase | ||
JNJ-7706621 是一种aurora kinase 抑制剂,有效抑制CDK1和CDK2,对CDK1,CDK2,aurora-A 和aurora-B 的IC50值分别为 9 nM,3 nM,11 nM 和 15 nM。 | |||
T6458 | VEGFR FLT CDK S6 Kinase Aurora Kinase | ||
CYC116是一种有效的极光激酶 A 和 B 的抑制剂,Ki 值分别为8和9 nM。 | |||
T15815 | Aurora Kinase | ||
LY3295668 (AK-01) 是 Aurora A 的选择性抑制剂,对 Aurora A 和 B 的 Kis 分别为 0.8 nM 和 1038 nM。 | |||
T6767 | Apoptosis Aurora Kinase | ||
TCS7010 (Aurora A Inhibitor I) 是一种选择性的 Aurora A 抑制剂,IC50值为 3.4 nM。 | |||
T3068 | Apoptosis FLT JAK Bcr-Abl Aurora Kinase Autophagy | ||
AT9283 (J-504568) 是一种多靶点激酶抑制剂,抑制多种实体瘤在体内外的生长和存活,有效抑制Aurora A/B,JAK2/3,Abl (T315I),和Flt3,IC50值范围为 1-30 nM。 | |||
T2241 | Apoptosis Aurora Kinase Autophagy | ||
Alisertib (MLN 8237) 是一种口服活性和选择性的Aurora A 激酶抑制剂,IC50值为 1.2 nM。它通过靶向白血病细胞中的AKT/mTOR/AMPK/p38途径诱导其凋亡和自噬,具有抗肿瘤活性。 | |||
T10215 | Apoptosis PLK Aurora Kinase | ||
AAPK-25 是选择性的Aurora/PLK 激酶双重抑制剂,显示出抗肿瘤活性。它可造成有丝分裂延迟并阻滞前中期细胞,通过生物标志物组蛋白 H3Ser10磷酸化反应,导致细胞凋亡激增。 | |||
T2094 | FGFR Trk receptor c-RET Bcr-Abl Aurora Kinase Autophagy | ||
Danusertib (PHA-739358) 是一种极光激酶抑制剂,能够抑制 Aurora A、Aurora B 和 Aurora C 的活性,IC50值分别为 13、79 和 61 nM。它是一种具有潜在抗肿瘤活性的小分子 3-氨基吡唑衍生物。 | |||
T66175 | GSK-3 Antibiotic Aurora Kinase | ||
Ceftriaxone Sodium 是一种广谱 β-内酰胺类三代头孢菌素类抗生素 (antibiotic),具有抗炎、抗肿瘤、抗菌和抗氧化活性。Ceftriaxone Sodium 是一种共价 GSK3β和 Aurora B 抑制剂, 可用于研究败血症和感染性心内膜炎。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01413 | H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) | Mouse | HEK293 | ||
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its self-assembling nature.
|
|||||
TMPK-01412 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.
|
|||||
TMPK-01416 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.
|